Information Provided By:
Fly News Breaks for November 9, 2015
INCY
Nov 9, 2015 | 07:35 EDT
Jefferies analyst Brian Abrahams calls Friday's 14% pullback in shares of Incyte an overreaction. The Street may have asked for too much from the immature epacadostat dataset, Abrahams tells investors in a research note. The data still suggests added activity in large-market solid tumor indications, the analyst contends. He thinks the drug can find a place in the treatment paradigm and keeps a Buy rating on Incyte with a $142 price target. The stock closed Friday down $16.55 to $100.21.
News For INCY From the Last 2 Days
INCY
INCY
INCY
INCY
INCY
INCY
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.